The Dalkon Shield Scandal: A Medical Device Company's Suppressed Data

In a Minnesota courtroom in 1984, a federal judge named Miles Lord did something judges are not supposed to do. Having presided over a run of lawsuits against the A.H. Robins Company, maker of a contraceptive device called the Dalkon Shield, he asked three of the company’s senior executives to stand and listen while he read them a statement. “You have taken the bottom line as your guiding beacon and the low road as your route,” he told them, in what became known as his “reprimand”. “Please, in the name of humanity, lift your eyes.” The device at the centre of the case was a small crab-shaped piece of plastic, barely larger than a coin, that had been sold to millions of women as a safe modern alternative to the pill. By the time Judge Lord spoke, it was linked to tens of thousands of serious infections, an unknown number of ruined pregnancies, and a stack of deaths. This is the story of that device, of the data the company had and did not share, and of how a genuine corporate cover-up became the reference point for an entire era’s mistrust of medicine done to women.

A device sold on a promise

The Dalkon Shield was an intrauterine device, or IUD — a small object placed inside the womb to prevent pregnancy. IUDs had been around for decades by the early 1970s, and they were having a moment. The contraceptive pill, barely a decade old, was under a cloud of anxiety about blood clots and hormones, and many women and doctors wanted a non-hormonal option. Into that gap came the Shield, designed in the late 1960s and marketed from 1971 by the A.H. Robins Company, a respected old pharmaceutical firm based in Richmond, Virginia, better known until then for a cough medicine and a lip balm.

Robins bought the rights to the device and sold it hard, on two claims: that it was highly effective at preventing pregnancy, and that it was safe. The effectiveness figures in the early promotion were strikingly low failure rates, and they turned out to be built on thin and flattering data — a small early study by the device’s co-inventor, run over a short period, whose numbers did not survive contact with wider use. Millions of the devices were sold in the United States and abroad in just a few years. Women trusted it because their doctors offered it, and their doctors offered it because a reputable company said it was safe.

The thread that wicked

The kernel of this scandal is unusually physical — you can hold the fatal flaw in your hand and understand it. Most of the harm traced to a single design feature: the tail string.

Every IUD has a string or thread hanging down through the cervix into the vagina, so that a woman or her doctor can check the device is in place and remove it. On most devices this thread was a single filament — one solid strand. The Dalkon Shield’s thread was different. It was multifilament: many fine fibres encased in a nylon sheath. That construction created a problem that its designers appear not to have fully anticipated and that the company came to understand alarmingly early. The sheath could break down or admit fluid, and the space between the fibres could act as a wick, drawing bacteria upward from the vagina, which is not sterile, into the uterus, which normally is. The medical term for the resulting infection is pelvic inflammatory disease, and it can be severe: it can scar the fallopian tubes and cause infertility, it can turn septic, and in a pregnant woman it can be lethal.

The specific horror that made headlines involved women who became pregnant despite the device — the effectiveness having been oversold — and who, with the Shield still in place, suffered infected miscarriages in the middle trimester. These septic spontaneous abortions were the worst outcome, and several women died of them. Others were left infertile by infections that ravaged their reproductive organs. The counting is imprecise and the totals are contested, but serious injuries reached into the tens of thousands, and the litigation that followed would eventually involve hundreds of thousands of claims.

What the company knew

Here is what lifts this from a tragic engineering error into a documented cover-up, and it is why the case still matters. Robins did not merely fail to foresee the wicking problem. Internal records, dragged into the open by litigation, showed that concern about the multifilament thread’s capacity to wick bacteria had been raised inside the company and its circle early — that the danger of the design had surfaced as a real possibility and had then been left unpursued and undisclosed. The company also had internal knowledge that the flattering effectiveness figures were unreliable while continuing to promote them.

The suppression of unfavourable data became the spine of the plaintiffs’ case. As lawsuits multiplied through the late 1970s and into the 1980s, discovery forced Robins to produce internal documents, and the picture they painted was of a company that had reasons for concern about both the safety and the effectiveness claims and had not acted on them with anything like the urgency the situation demanded. There were also allegations, aired in the litigation, that documents had been destroyed or withheld, and Judge Lord’s extraordinary courtroom reprimand grew directly out of his conviction that the company had concealed evidence and dragged its feet while women kept being hurt.

The device had, in the meantime, been effectively removed from the market. Robins suspended US sales of the Shield in 1974 amid the mounting reports, though huge numbers of devices remained implanted in women who had no idea they were carrying a hazard, and the company was slow and grudging about urging their removal. It later mounted a recall campaign, but years after the sales stopped and after much of the damage was done.

The mechanism of exposure

The way this scandal broke open is worth dwelling on, because it changed the law. Unlike a drug, a medical device in the early 1970s faced remarkably little regulatory scrutiny before it could be sold. When the Dalkon Shield launched, the US Food and Drug Administration had no clear authority to require pre-market safety testing of a device like this; the modern framework for regulating medical devices did not yet exist. The Shield was, in a real sense, sold into a regulatory void.

That void is part of why the exposure came almost entirely through the courts rather than through any watchdog. It was individual women, and the lawyers who took their cases, who forced the internal documents out — file by file, deposition by deposition. The litigation also became a landmark in its own right for the use of punitive damages, the extra sum a jury can award to punish conduct it finds outrageous, over and above any compensation for the injury itself. Juries hearing what Robins had known and withheld returned punitive awards that signalled how the internal record read to ordinary citizens: as the story of a company that had chosen the balance sheet over the women using its product, with nothing accidental about it. The sheer weight of the litigation eventually became existential for the company. Facing an unmanageable tide of claims, A.H. Robins filed for bankruptcy in 1985. The bankruptcy, as in later pharmaceutical reckonings, doubled as a mechanism of accounting: it led to the creation of a claimants’ trust, eventually funded with around 2.4 billion dollars, to compensate the injured women — one of the largest such arrangements of its era. Robins itself was later absorbed by another company. And the scandal was a direct spur to the strengthening of medical-device regulation, feeding into the Medical Device Amendments and the tighter pre-market rules that followed, so that a device could no longer reach a woman’s body quite so easily on a company’s unexamined say-so.

Where the story grew in the telling

Now the fork, and with this case it is a delicate one, because the documented core is so damning that there is little temptation to exaggerate the company’s guilt — and yet the popular memory did drift, in a particular direction worth naming.

The Dalkon Shield became, deservedly, a symbol. But over the following decades the symbol did some work the specific facts do not support, hardening into a general indictment of the intrauterine device as a category. For a generation of American women and doctors, “IUD” became almost synonymous with danger, and the modern, well-designed, single-filament devices that are among the safest and most effective contraceptives available were tarred by association with a single badly made product from the 1970s. The wicking multifilament thread was the villain; the concept of an IUD was not. That conflation — reasonable as fear, wrong as fact — measurably slowed the adoption of good contraception for years, particularly in the United States, where the shadow lingered longest.

There is a second, quieter drift. The Shield is sometimes folded into a sweeping narrative in which every reproductive technology offered to women is presumed to be a corporate trap. That narrative draws real strength from this case, because here it was substantially true. But used as a template applied everywhere, it can slide from justified specific mistrust into a generalised suspicion that does its own harm — the same overreach that turns the genuine thalidomide cover-up into a blanket fear of all medication, or the real opioid marketing scandal into a reflex that no pain should ever be treated. The lesson of a specific betrayal is not that everything is a betrayal.

What the case was really about

Strip it back and the Dalkon Shield is not, at bottom, a story about a piece of plastic. It is a story about who gets believed, and how long it takes.

The women who first reported severe infections, ectopic pregnancies and septic miscarriages were describing something a company had internal reason to suspect and a regulatory system had no power to catch. For years those women were, in the aggregate, not believed quickly enough — their injuries absorbed as individual misfortune rather than assembled into the pattern they formed. The pattern only became undeniable when enough of them found lawyers, and the lawyers found the memos. The mistrust of medicine done to women that the Shield helped crystallise was not paranoia. It was pattern recognition, learned the hard way, from a case where the suspicion turned out to be exactly right.

That is the difficult inheritance of the Dalkon Shield. It taught a generation to distrust, and the distrust was earned. The task it leaves behind is the hardest one: to carry the memory of a real betrayal without letting it curdle into a suspicion of everything, to remember why the fear was justified without letting the fear outlive its facts. A company suppressed what it knew, women were gravely hurt, and the courts — not the regulators — finally pulled the truth into the light. Understanding how that happened, and what it cost, matters more than any single verdict a jury ever returned.